This month: texts fail to up adherence, unstable AF risks, survival win for SGLT2 therapy in real-world HFrEF patients, and ...

MONTREAL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Velan Inc. (TSX: VLN) (“Velan” or the “Company”), a world-leading manufacturer of ...

Enters into definitive agreement with an affiliate of Global Risk Capital to divest its asbestos-related liabilities at a cost of US$143 ...